Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57]

Atherosclerosis. 2016 Oct:253:345. doi: 10.1016/j.atherosclerosis.2016.05.012. Epub 2016 May 20.

Affiliations

¹ Resverlogix Corp., Calgary, Canada.
² Resverlogix Corp., San Francisco, USA.
³ Resverlogix Corp., Calgary, Canada. Electronic address: norm@resverlogix.com.

PMID: 27211480
DOI: 10.1016/j.atherosclerosis.2016.05.012

No abstract available

Publication types

Published Erratum